DXVX Accelerates Introduction of 'Anticancer Vaccine' Technology Developed by UK Affiliate

DXVX announced on the 28th that it has completed on-site due diligence for the technology transfer of the anticancer vaccine OVM-200 developed by Oxford BioMedica (OM) in the UK, as well as discussions for joint research with the University of Oxford.

The due diligence team led by Shim Sung-nyeo, Head of Product Development at DXVX, conducted on-site inspections in the UK from mid-last month, visiting OVM, the University of Oxford, and Eurofins CDMO, which is responsible for contract development and manufacturing (CDMO). During this on-site due diligence, DXVX directly confirmed the safety and efficacy of OVM-200 by reviewing the patent for the core technology of OVM, recombinant overlapping peptides (ROP), the results of the UK Phase 1a clinical trial, and the progress of Phase 1b. Discussions were also held on cooperation plans between the two companies for domestic and international clinical trials, including Phase 1b and Phase 2, after technology transfer. Through the manufacturing facility Eurofins, DXVX also reviewed plans for the production and stable supply of clinical drugs to be used in clinical trials.

Discussions on collaboration plans with OVM and scientists from the University of Oxford were also conducted. DXVX plans to actively build a cooperative relationship by agreeing to proceed with new joint research projects with the University of Oxford’s expert research team for the development of innovative new drug pipelines.

A DXVX official stated, “With the successful completion of this due diligence, we expect to proceed more quickly with the contract for the introduction of the anticancer vaccine from OVM, as well as to swiftly advance the next stages of clinical trials domestically and internationally, enabling us to focus on the commercialization of the first anticancer vaccine within our group.”